Barr Laboratories

(BRL)

has received approval from the

Food and Drug Administration

for two oral contraceptives.

Barr will manufacture and market generic versions of

Ortho-McNeil Pharmaceutical's

Ortho-Novum 1/35 tablets and Modicon-28 tablets. Barr, which is based in Pomona, N.Y., will market both drugs as branded generics with the

Nortrel

trademark. The drugs will be available in the fourth quarter of fiscal 2001.

The two drugs have current annual sales of about $80 million, according to Barr.

In recent trading on the

New York Stock Exchange

, Barr gained $2.34, or 4.6%, to $52.85.